ACM
TBIO

AlphaCrest Capital Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

AlphaCrest Capital Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-30,500
Closed -$562K – 1359
2020
Q4 		$562K Buy
+30,500
New +$546K 0.05% 587

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

AlphaCrest Capital Management's TBIO Position: Q1 2021 in Review

AlphaCrest Capital Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q1 2021, closing a stake of 30,500 shares — an estimated $562K sold.

AlphaCrest Capital Management first reported a position in TBIO in Q4 2020 and held it in 1 quarter. The position peaked at $562K in Q4 2020. 146 funds tracked by Wall St. Rank hold TBIO as of Q1 2021.

  • AlphaCrest Capital Management reported no remaining Translate Bio, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 30,500 Translate Bio, Inc. Common Stock shares in Q1 2021, an estimated $562K.
  • AlphaCrest Capital Management first reported a position in Translate Bio, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • AlphaCrest Capital Management's Translate Bio, Inc. Common Stock position peaked at $562K in Q4 2020.
  • 146 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q1 2021.

Based on AlphaCrest Capital Management's 13F filing for Q1 2021, filed 13 May 2021.